Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in Q1 2025 from $18.8 billion in Q4 2024 to $37.7 billion. However, drugmakers remain hesitant to pursue larger-scale transactions. The total deal value in Q1 2025 was 32% lower compared to Q1 2024, as larger M&As are seen as high risk due to the current US political landscape, according to GlobalData, a leading data and analytics company. According to GlobalData’s report “Pharma M&A Trends – Q1 2025,” oncology remains the leading therapeutic area in Q1 2025, with most of the deals targeting cancer-related assets.
Read the full article: Pharma M&A Deal Value Surges by 101% QoQ in Q1 2025 Despite US Political Turbulence //
Source: https://www.globaldata.com/media/business-fundamentals/pharma-ma-deal-value-surges-101-qoq-q1-2025-despite-us-political-turbulence-reveals-globaldata/